SLT Holdings LLC Buys Shares of 31,000 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

SLT Holdings LLC bought a new stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 31,000 shares of the company’s stock, valued at approximately $66,000. SLT Holdings LLC owned about 0.05% of Black Diamond Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BDTX. Vestal Point Capital LP boosted its holdings in Black Diamond Therapeutics by 139.5% in the third quarter. Vestal Point Capital LP now owns 5,028,500 shares of the company’s stock worth $21,874,000 after acquiring an additional 2,928,500 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Black Diamond Therapeutics by 12.2% in the third quarter. Geode Capital Management LLC now owns 944,877 shares of the company’s stock worth $4,111,000 after acquiring an additional 102,445 shares in the last quarter. State Street Corp boosted its holdings in Black Diamond Therapeutics by 17.2% in the third quarter. State Street Corp now owns 809,196 shares of the company’s stock worth $3,520,000 after acquiring an additional 118,764 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Black Diamond Therapeutics in the third quarter worth about $3,032,000. Finally, Bank of New York Mellon Corp boosted its holdings in Black Diamond Therapeutics by 46.1% in the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company’s stock worth $443,000 after acquiring an additional 65,341 shares in the last quarter. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Stock Down 1.1 %

Black Diamond Therapeutics stock opened at $1.88 on Friday. Black Diamond Therapeutics, Inc. has a 52 week low of $1.77 and a 52 week high of $7.66. The company has a market capitalization of $106.38 million, a price-to-earnings ratio of -1.41 and a beta of 2.52. The stock has a 50-day moving average price of $2.23 and a 200 day moving average price of $3.18.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. Research analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wedbush reissued an “outperform” rating and issued a $11.00 price target (down previously from $16.00) on shares of Black Diamond Therapeutics in a report on Friday. Stifel Nicolaus lowered their price target on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.40.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.